CAR T-cell therapies represent a potent treatment option for patients with heavily pretreated relapsed/refractory hematologic malignancies, however, the infection risk associated with treatment may hinder the efficacy of COVID-19 vaccines in this population.
Ruxolitinib and belumosudil represent FDA-approved treatment options to manage cGVHD, however, real world data will determine best practices for treatment and future research directions within the space.
The recently launched phase 2 ACE-Breast03 seeks to appraise the efficacy and safety of the novel antibody-drug conjugate, ARX788, in patients with metastatic HER2-positive breast cancer whose disease is resistant to previous targeted therapies.
Combining immunotherapy with other targeted therapies may result in more promising outcomes than immunotherapy alone in the treatment of recurrent ovarian cancer, according to an expert at University of California, Los Angeles.
An expert from The University of Texas MD Anderson Cancer Center recently highlighted the ramifications of the phase 2 ReDOS trial, the need for molecular profiling in mCRC, and ongoing research on the combination of TKIs and checkpoint inhibitors.